CLINICAL AND CELL KINETIC DATA ON COMBINATION OF CYTOSINE-ARABINOSIDE WITH DAUNORUBICIN, IFOSFAMIDE, THIOGUANINE, AND VINCRISTINE FOR REMISSION INDUCTION AND MAINTENANCE IN PATIENTS WITH ACUTE MYELOCYTIC-LEUKEMIA

被引：11
|
作者：
BUCHNER, T
KAMANABROO, D
URBANITZ, D
HIDDEMANN, W
VANDELOO, J
机构：
来源：
BLUT | 1978年 / 36卷 / 06期
关键词：
D O I：
10.1007/BF01000596
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：371 / 376
页数：6
相关论文
共 50 条
  • [41] Impact of cytosine-arabinoside (Ara-C) dose given at induction+/-consolidation before allogeneic or autologous stem cell transplantation (SCT) for acute myeloblastic leukemia in first remission
    Cahn, JY
    Labopin, M
    Gorin, NC
    BLOOD, 1997, 90 (10) : 1002 - 1002
  • [42] High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia:: impact of cytogenetics on achieving a complete remission
    Stein, AS
    O'Donnell, MR
    Slovak, ML
    Nademanee, A
    Dagis, A
    Schmidt, GM
    Parker, PM
    Snyder, DS
    Smith, EP
    Somlo, G
    Margolin, KA
    Arber, D
    Niland, J
    Forman, SJ
    LEUKEMIA, 2000, 14 (07) : 1191 - 1196
  • [43] High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission
    AS Stein
    MR O'Donnell
    ML Slovak
    A Nademanee
    A Dagis
    GM Schmidt
    PM Parker
    DS Snyder
    EP Smith
    G Somlo
    KA Margolin
    D Arber
    J Niland
    SJ Forman
    Leukemia, 2000, 14 : 1191 - 1196
  • [44] DEFINITION OF REFRACTORINESS AGAINST CONVENTIONAL CHEMOTHERAPY IN ACUTE MYELOID-LEUKEMIA - A PROPOSAL BASED ON THE RESULTS OF RETREATMENT BY THIOGUANINE, CYTOSINE-ARABINOSIDE, AND DAUNORUBICIN (TAD 9) IN 150 PATIENTS WITH RELAPSE AFTER STANDARDIZED 1ST LINE THERAPY
    HIDDEMANN, W
    MARTIN, WR
    SAUERLAND, CM
    HEINECKE, A
    BUCHNER, T
    LEUKEMIA, 1990, 4 (03) : 184 - 188
  • [45] USE OF A 4'-(9 ACRIDINYLAMINO) METHANESULFON-META-ANISIDIDE (AMSA), CYTOSINE-ARABINOSIDE (ARA-C) VINCRISTINE PREDNISONE COMBINATION (AMSA-OAP) IN POOR RISK PATIENTS IN ACUTE-LEUKEMIA
    MCCREDIE, KB
    KEATING, MJ
    ESTEY, EH
    ZANDER, A
    BODEY, GP
    DREWINKO, B
    FREIREICH, EJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 479 - 479
  • [46] STUDY OF CYTOSINE-ARABINOSIDE (NSC-63878) SYNCHRONIZATION PLUS VINCRISTINE (NSC-67574), PREDNISONE (NSC-10023), AND L-ASPARAGINASE (NSC-109229) FOR REMISSION INDUCTION IN ADVANCED ACUTE-LEUKEMIA IN CHILDREN
    SUTOW, WW
    THOMAS, D
    STEUBER, CP
    PULLEN, J
    VATS, T
    BRYAN, JH
    MORGAN, SK
    CANCER TREATMENT REPORTS, 1976, 60 (05): : 591 - 594
  • [47] HIGH-DOSE VERSUS INTERMEDIATE-DOSE CYTOSINE-ARABINOSIDE IN COMBINATION WITH MITOXANTRONE FOR THE TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA - PRELIMINARY CLINICAL AND PHARMACOLOGICAL DATA OF A RANDOMIZED COMPARISON
    HIDDEMANN, W
    SCHLEYER, E
    UHRMEISTER, C
    AUL, CH
    MASCHMEYER, G
    HEINECKE, A
    BUCHNER, T
    CANCER TREATMENT REVIEWS, 1990, 17 (2-3) : 279 - 285
  • [48] Phase III randomized study of all-trans retinoic acid (ATRA) vs daunorubicin (D) end cytosine arabinoside (A) as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia (APL).
    Tallman, MS
    Andersen, J
    Schiffer, CA
    Appelbaum, FR
    Feusner, JE
    Woods, WG
    Ogden, A
    Weinstein, H
    Shepherd, L
    Rowe, JM
    Wiernik, PH
    BLOOD, 1995, 86 (10) : 488 - 488
  • [49] Induction/maintenance with ATRA/As2O3 combination yields a high quality clinical/molecular remission and disease-free survival in newly diagnosed patients with acute promyelocytic leukemia.
    Shi, ZZ
    Shen, ZX
    Fang, J
    Gu, BW
    Zhu, YM
    Chen, Y
    Li, JM
    Shen, Y
    Wu, W
    Tang, W
    de The, H
    Wang, ZY
    Chen, Z
    Chen, SJ
    BLOOD, 2003, 102 (11) : 141A - 142A
  • [50] High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)
    Willemze, Roelof
    Suciu, Stefan
    Mandelli, Franco
    Labar, Boris
    Marie, Jean-Pierre
    Mistrik, Martin
    Liso, Vincenzo
    Fabbiano, Francesco
    Nobile, Francesco
    Sborgia, Marco
    Rotoli, Bruno
    Selleslag, Dominik L. D.
    Lefrere, Francois, Sr.
    Peta, Antonio
    Martelli, Massimo F.
    Leone, Giuseppe
    Cantore, Nicola
    Beksac, Meral
    Zwi, Berneman
    Thomas, Xavier
    Greco, Michele Mario
    Bron, Dominique
    Fillet, Georges
    Guimaraes, Jose E.
    Muus, Petra
    Fazi, Paola
    Baila, Liliana
    Vignetti, Marco
    Amadori, Sergio
    de Witte, Theo
    Meloni, Giovanna
    BLOOD, 2008, 112 (11) : 55 - 56
12345